New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
David S.P. Tan(National University of Singapore), Stan B. Kaye(Institute of Cancer Research), Rowan Miller(Queen Mary University of London)
Cited by 89
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|Annals of Oncology|2020|478
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
|Nature Communications|2016|386